David M. Hilbert, Ph.D., Chief Scientific Officer

Dr. Hilbert is Zyngenia's CSO and head of research and development. Dr. Hilbert came to Zyngenia in 2009 after four years as an independent biotechnology consultant assisting companies with the many strategic, scientific, and operational challenges associated with drug development. Prior to his consulting endeavors, Dr. Hilbert was the Vice President of Research and a member of the senior management team at Cellective Therapeutics, a start-up antibody company acquired by MedImmune in October 2005. Dr. Hilbert began his biotech career at Human Genome Sciences (HGS) where he spent 8 years guiding the preclinical development of antibodies and genomics-based therapeutics. As Vice President, Research at HGS, Dr. Hilbert directed the drug discovery, target validation, assay development, toxicology, pharmacokinetics, clinical testing and animal husbandry functions. At Human Genome Sciences, Dr Hilbert led the transformation of the company from a genomics research company to an integrated drug development organization. He filed the first IND for the company and was pivotally involved in the development of ABthrax and Benlysta. Prior to joining HGS, Dr. Hilbert was a Staff Fellow in the National Cancer Institute, NIH where he investigated neoplastic transformation of B lymphocytes. Dr. Hilbert received his B.S. from Haverford College and his Ph.D. from the University of Pennsylvania.